The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Standard
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. / Straver, [Unbekannt]; Marieke, E; Glas, [Unbekannt]; Annuska, M; Hannemann, Juliane; Juliane, [Unbekannt]; Wesseling, [Unbekannt]; Jelle, [Unbekannt]; Vijver, van de; Marc, J; Rutgers, [Unbekannt]; Emiel, J Th; Vrancken, Peeters; Marie-Jeanne, T F D; Tinteren, van; Harm, [Unbekannt]; Van't, Veer; Laura, J; Rodenhuis, [Unbekannt]; Sjoerd, [Unbekannt].
in: BREAST CANCER RES TR, Jahrgang 119, Nr. 3, 3, 2010, S. 551-558.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
AU - Straver, [Unbekannt]
AU - Marieke, E
AU - Glas, [Unbekannt]
AU - Annuska, M
AU - Hannemann, Juliane
AU - Juliane, [Unbekannt]
AU - Wesseling, [Unbekannt]
AU - Jelle, [Unbekannt]
AU - Vijver, van de
AU - Marc, J
AU - Rutgers, [Unbekannt]
AU - Emiel, J Th
AU - Vrancken, Peeters
AU - Marie-Jeanne, T F D
AU - Tinteren, van
AU - Harm, [Unbekannt]
AU - Van't, Veer
AU - Laura, J
AU - Rodenhuis, [Unbekannt]
AU - Sjoerd, [Unbekannt]
PY - 2010
Y1 - 2010
N2 - The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.
AB - The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.
M3 - SCORING: Zeitschriftenaufsatz
VL - 119
SP - 551
EP - 558
JO - BREAST CANCER RES TR
JF - BREAST CANCER RES TR
SN - 0167-6806
IS - 3
M1 - 3
ER -
